GleamWall
中文EN

KROS Keros Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1664710 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-83.4%
TTM net income YoY-195.8%
TTM EPS YoY-248.7%
Revenue 3-yr CAGR1,616.0%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-181.3%
Net margin-152.7%
FCF margin-119.4%
EBITDA margin-177.3%

Returns

ROE-12.6%
ROA-11.8%
ROIC (approx.)-389.2%
Asset turnover0.08x

Leverage & solvency

Liabilities / assets9.2%
Debt / equity0.00x
Current ratio18.14x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio-2.6%
Payout ratio—
Capex / revenue1.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$243.86M$0
R&D expense$129.64M$173.63M
SG&A expense$46.85M$40.75M
Operating income$67.57M-$210.83M
Interest expense—$0
Pretax income$91.90M-$187.05M
Income tax$4.88M$300,000
Net income$87.01M-$187.35M
EBITDA$69.08M-$209.60M
EPS (basic)2.34-5.00
EPS (diluted)2.30-5.00
Weighted avg. shares (diluted)37.86M37.44M
Balance sheet
Cash & equivalents$287.42M$561.38M
Receivables$3.57M$2.74M
Current assets$315.43M$588.89M
PP&E, net$4.30M$4.24M
Total assets$338.02M$615.89M
Current liabilities$20.41M$27.45M
Total liabilities$34.89M$44.33M
Shareholders' equity$303.13M$571.55M
Shares outstanding19.54M40.55M
Cash flow statement
Operating cash flow$107.50M-$160.87M
Capital expenditure$1.55M$1.93M
Free cash flow$105.95M-$162.80M
Investing cash flow-$1.55M-$1.93M
Financing cash flow-$378.47M$391.82M
Depreciation & amortization$1.51M$1.23M
Stock-based compensation$28.70M$34.87M
Share buybacks$375.00M$0

Free plan shows the latest 2 periods; Pro shows all 7 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.